Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Cosmo's Partner RedHill announces approval of Talicia® for the treatment of H. Pylori in adults in the USA

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/04/2019 | 06:50am EST

Cosmo's Partner RedHill announces approval of Talicia® for the treatment of H. Pylori in adults in the USA

Dublin, Ireland - November 4, 2019 - Cosmo Pharmaceuticals N.V. (SIX: COPN) today informs that its partner RedHill Biopharma (NASDAQ: RDHL, Tel-Aviv Stock Exchange: RDHL) today announced that the U.S. Food and Drug Administration (FDA) has approved Talicia® (omeprazole magnesium1 10.3 mg, amoxicillin 250 mg and rifabutin 12.5 mg) delayed-release capsules for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Talicia® is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies. It is estimated that H. pylori resistance to clarithromycin more than doubled between 2009-2013.

Talicia® is eligible for 8 years of U.S. market exclusivity under QIDP designation, in addition to patent protection extending until 2034.

RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment for H. pylori infection in adults, targeting more than two million patients estimated to be treated for
H. pylori infection annually.

Cosmo announced on October 18, 2019, that it had taken a 19.56% stake in RedHill and had licensed out Aemcolo to RedHill.




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COSMO PHARMACEUTICALS N.V.
01/22COSMO PHARMACEUTICALS N : Methylene Blue MMX regulatory update Substantial align..
AQ
01/21COSMO PHARMACEUTICALS METHYLENE BLUE : Substantial alignment reached with FDA on..
TE
01/13Acacia Pharma enters into strategic in-licensing, investment and loan transac..
AQ
01/13Cosmo sub-licenses its ByFavo US rights to Acacia Pharma, takes an initial 14..
AQ
01/10Boeing faces fresh scandal
01/10Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma..
TE
2019RedHill Biopharma Initiates U.S. Promotion of Aemcolo for Travelers' Diarrhea
AQ
2019COSMO PHARMACEUTICALS N : announces worldwide exclusive Distribution Agreement f..
AQ
2019Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement fo..
TE
2019COSMO PHARMACEUTICALS N : appoints New CSO; as current CSO retires
PU
More news
Financials (EUR)
Sales 2019 47,1 M
EBIT 2019 -17,4 M
Net income 2019 -27,6 M
Finance 2019 119 M
Yield 2019 -
P/E ratio 2019 -40,5x
P/E ratio 2020 -125x
EV / Sales2019 20,6x
EV / Sales2020 12,0x
Capitalization 1 090 M
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 100,04  €
Last Close Price 74,53  €
Spread / Highest target 73,7%
Spread / Average Target 34,2%
Spread / Lowest Target -2,86%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.4.17%1 203
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG3.03%284 454
PFIZER1.63%220 369
MERCK AND COMPANY-5.46%218 904
NOVARTIS-0.38%213 484